12:00 AM
May 28, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Levemir insulin detemir regulatory update

Novo Nordisk said FDA approved an expanded label for Levemir insulin detemir to include treatment of Type I diabetes in children ages 2-5 years. The long-acting insulin analog is...

Read the full 121 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >